Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Use of narrative medicine to identify key factors for effective doctor-patient relationships in severe asthma.

Cappuccio A, Napolitano S, Menzella F, Pellegrini G, Policreti A, Pelaia G, Porpiglia PA, Marini MG; SOUND GROUP.

Multidiscip Respir Med. 2019 Sep 2;14:26. doi: 10.1186/s40248-019-0190-7. eCollection 2019.

2.

One year of mepolizumab. Efficacy and safety in real-life in Italy.

Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C, Bucca C, Heffler E, Paoletti G, Testino E, Manfredi A, Caruso C, Guida G, Senna G, Bonavia M, Riccio AM, Canonica GW, Passalacqua G.

Pulm Pharmacol Ther. 2019 Oct;58:101836. doi: 10.1016/j.pupt.2019.101836. Epub 2019 Aug 29.

PMID:
31473366
3.

Targeting eosinophils: severe asthma and beyond.

Caminati M, Menzella F, Guidolin L, Senna G.

Drugs Context. 2019 Jul 23;8:212587. doi: 10.7573/dic.212587. eCollection 2019. Review.

4.

Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia.

Villafuerte D, Aliberti S, Soni NJ, Faverio P, Marcos PJ, Wunderink RG, Rodriguez A, Sibila O, Sanz F, Martin-Loeches I, Menzella F, Reyes LF, Jankovic M, Spielmanns M, Restrepo MI; GLIMP Investigators.

Respirology. 2019 Aug 5. doi: 10.1111/resp.13663. [Epub ahead of print]

PMID:
31385399
5.

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab.

Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, Bagnasco D, Facciolongo N.

Ther Clin Risk Manag. 2019 Jul 10;15:869-875. doi: 10.2147/TCRM.S207402. eCollection 2019.

6.

Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation.

Bagnasco D, Menzella F, Caminati M, Caruso C, Guida G, Bonavia M, Riccio A, Milanese M, Manfredi A, Senna G, Passalacqua G.

Allergy. 2019 Jun 5. doi: 10.1111/all.13937. [Epub ahead of print] No abstract available.

PMID:
31166605
7.

Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.

Colombo GL, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Bruno GM, Pitotti C, Menzella F.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841350. doi: 10.1177/1753466619841350.

8.

Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?

Menzella F, Latorre M, Ruggiero P, Bagnasco D, Heffler E.

Expert Opin Biol Ther. 2019 Jul;19(7):601-606. doi: 10.1080/14712598.2019.1613367. Epub 2019 May 27.

PMID:
31033373
9.

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Menzella F, Biava M, Bagnasco D, Galeone C, Simonazzi A, Ruggiero P, Facciolongo N.

Drugs Context. 2019 Apr 15;8:212580. doi: 10.7573/dic.212580. eCollection 2019. Review.

10.

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.

Lombardi C, Bagnasco D, Caruso C, D'Amato M, Menzella F, Milanese M, Senna G, Canonica GW, Passalacqua G.

Pulm Pharmacol Ther. 2019 Feb;54:87-89. doi: 10.1016/j.pupt.2018.12.003. Epub 2018 Dec 29.

PMID:
30597278
11.

Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.

Katsaounou P, Odemyr M, Spranger O, Hyland ME, Kroegel C, Conde LG, Gore R, Menzella F, Domingo Ribas C, Morais-Almeida M, Gasser M, Kasujee I.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00076-2018. doi: 10.1183/23120541.00076-2018. eCollection 2018 Oct. Erratum in: ERJ Open Res. 2019 Feb 01;5(1):.

12.

Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective.

Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, Aliberti S, Restrepo MI; GLIMP Study Group.

BMC Infect Dis. 2018 Dec 18;18(1):677. doi: 10.1186/s12879-018-3565-z.

13.

Severe refractory asthma: current treatment options and ongoing research.

Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M.

Drugs Context. 2018 Dec 5;7:212561. doi: 10.7573/dic.212561. eCollection 2018. Review.

14.

The Severe Asthma Network in Italy: Findings and Perspectives.

Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, Senna G, Canonica GW; SANI Network.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468. doi: 10.1016/j.jaip.2018.10.016. Epub 2018 Oct 25.

PMID:
30368004
15.

Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report.

Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N.

Multidiscip Respir Med. 2018 Sep 1;13:32. doi: 10.1186/s40248-018-0145-4. eCollection 2018.

16.

Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology?

Galeone C, Scelfo C, Bertolini F, Caminati M, Ruggiero P, Facciolongo N, Menzella F.

Biomed Res Int. 2018 Jun 11;2018:4617565. doi: 10.1155/2018/4617565. eCollection 2018. Review.

17.

Heat-induced necrosis after bronchial thermoplasty: a new concern?

Menzella F, Lusuardi M, Galeone C, Montanari G, Cavazza A, Facciolongo N.

Allergy Asthma Clin Immunol. 2018 Jun 25;14:25. doi: 10.1186/s13223-018-0252-y. eCollection 2018.

18.

Towards precision medicine: The application of omics technologies in asthma management.

Scelfo C, Galeone C, Bertolini F, Caminati M, Ruggiero P, Facciolongo N, Menzella F.

Version 2. F1000Res. 2018 Apr 4 [revised 2018 Jan 1];7:423. doi: 10.12688/f1000research.14309.2. eCollection 2018.

19.

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma.

Facciolongo N, Di Stefano A, Pietrini V, Galeone C, Bellanova F, Menzella F, Scichilone N, Piro R, Bajocchi GL, Balbi B, Agostini L, Salsi PP, Formisano D, Lusuardi M.

BMC Pulm Med. 2018 Feb 8;18(1):29. doi: 10.1186/s12890-017-0554-8.

20.

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.

Menzella F, Galeone C, Lusuardi M, Simonazzi A, Castagnetti C, Ruggiero P, Facciolongo N.

Ther Clin Risk Manag. 2017 Nov 8;13:1489-1493. doi: 10.2147/TCRM.S149775. eCollection 2017.

21.

Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?

Menzella F, Lusuardi M, Galeone C, Facciolongo N.

Ther Clin Risk Manag. 2017 Sep 19;13:1213-1221. doi: 10.2147/TCRM.S144604. eCollection 2017. Review.

22.

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N.

J Asthma Allergy. 2017 Aug 30;10:237-247. doi: 10.2147/JAA.S144100. eCollection 2017. Review.

23.

Real-life Efficacy of Omalizumab After 9 Years of Follow-up.

Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L.

Allergy Asthma Immunol Res. 2017 Jul;9(4):368-372. doi: 10.4168/aair.2017.9.4.368.

24.

Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential.

Menzella F, Lusuardi M, Galeone C, Taddei S, Facciolongo N, Zucchi L.

Ther Adv Chronic Dis. 2016 Nov;7(6):260-277. Epub 2016 Aug 11. Review.

25.

The clinical profile of benralizumab in the management of severe eosinophilic asthma.

Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L.

Ther Adv Respir Dis. 2016 Dec;10(6):534-548. Epub 2016 Sep 9. Review.

26.

Clinical usefulness of mepolizumab in severe eosinophilic asthma.

Menzella F, Lusuardi M, Montanari G, Galeone C, Facciolongo N, Zucchi L.

Ther Clin Risk Manag. 2016 Jun 8;12:907-16. doi: 10.2147/TCRM.S86299. eCollection 2016. Review.

27.

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.

Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L.

J Asthma Allergy. 2015 Oct 8;8:105-14. doi: 10.2147/JAA.S40244. eCollection 2015. Review.

28.

Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report.

Facciolongo N, Menzella F, Lusuardi M, Piro R, Galeone C, Castagnetti C, Cavazza A, Carbonelli C, Zucchi L, Salsi PP.

Multidiscip Respir Med. 2015 Mar 8;10(1):9. doi: 10.1186/s40248-015-0002-7. eCollection 2015.

29.

Tailored therapy for severe asthma.

Menzella F, Lusuardi M, Galeone C, Zucchi L.

Multidiscip Respir Med. 2015 Jan 16;10(1):1. doi: 10.1186/2049-6958-10-1. eCollection 2015. Review.

30.

A budget impact analysis of bronchial thermoplasty for severe asthma in clinical practice.

Menzella F, Zucchi L, Piro R, Galeone C, Castagnetti C, Facciolongo N.

Adv Ther. 2014 Jul;31(7):751-61. doi: 10.1007/s12325-014-0135-7. Epub 2014 Jul 10.

PMID:
25009004
31.

Training and practice in bronchoscopy a national survey in Italy.

Facciolongo N, Piro R, Menzella F, Lusuardi M, Salio M, Agli LL, Patelli M.

Monaldi Arch Chest Dis. 2013 Sep-Dec;79(3-4):128-33.

32.

"Neurologist's contribution to the diagnosis of sine materia respiratory insufficiency: case report".

Carbonelli C, Zedde M, Cavazza A, Facciolongo N, Menzella F, Spaggiari L, Zucchi L.

BMC Pulm Med. 2012 Aug 8;12:42. doi: 10.1186/1471-2466-12-42.

33.

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy.

Carbonelli C, Montepietra S, Caruso A, Cavazza A, Feo C, Menzella F, Motti L, Zucchi L.

Monaldi Arch Chest Dis. 2012 Mar;77(1):29-31.

34.

Clinical audit on diagnostic accuracy and management of respiratory failure in COPD.

Menzella F, Facciolongo N, Lusuardi M, Piro R, Formisano D, Castagnetti C, Simonazzi A, Zucchi L.

Respir Care. 2012 Dec;57(12):2067-73. doi: 10.4187/respcare.01502.

35.

Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.

Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, Castagnetti C, Carbonelli C, Zucchi L.

Ther Adv Respir Dis. 2012 Apr;6(2):87-95. doi: 10.1177/1753465811429478. Epub 2012 Feb 9.

PMID:
22323442
36.

Long-term benefits of omalizumab in a patient with severe non-allergic asthma.

Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L.

Allergy Asthma Clin Immunol. 2011 May 24;7(1):9. doi: 10.1186/1710-1492-7-9.

37.

Eosinophilic infiltrate in a patient with severe Legionella pneumonia as a levofloxacin-related complication: a case report.

Facciolongo N, Menzella F, Castagnetti C, Cavazza A, Piro R, Carbonelli C, Zucchi L.

J Med Case Rep. 2010 Nov 11;4:360. doi: 10.1186/1752-1947-4-360.

38.

Omalizumab: when the non-responder is a late-responder.

Menzella F, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L.

Eur Ann Allergy Clin Immunol. 2009 Oct;41(5):155-9.

PMID:
20101930
39.

Combined immediate- and delayed-type hypersensitivity to metamizole.

Bellegrandi S, Rosso R, Mattiacci G, Zaffiro A, Di Sora F, Menzella F, Aiuti F, Paganelli R.

Allergy. 1999 Jan;54(1):88-90. No abstract available.

PMID:
10195371

Supplemental Content

Loading ...
Support Center